Literature DB >> 16292246

Contraceptive use--United States and territories, Behavioral Risk Factor Surveillance System, 2002.

Diana M Bensyl1, Danielle A Iuliano, Marion Carter, John Santelli, Brenda Colley Gilbert.   

Abstract

PROBLEM: Contraceptive use is an important determinant of unintended pregnancy. In the United States, approximately half of all pregnancies are unintended. Population-based information about contraceptive use patterns is limited at the state level. Information about contraceptive use for states can be used to guide the development of state programs and policies to decrease unintended pregnancy and the spread of sexually transmitted infections. Information about contraceptive use for specific subpopulations can be used to further refine state efforts to improve contraceptive use and subsequently decrease the occurrence of unintended pregnancy. REPORTING PERIOD: Data were collected in 2002 for men and women. DESCRIPTION OF SYSTEM: The Behavioral Risk Factor Surveillance System (BRFSS) is a random-digit--dialed, telephone survey of the noninstitutionalized U.S. population aged > or =18 years. All 50 states, the District of Columbia, Guam, the Commonwealth of Puerto Rico, and the U.S. Virgin Islands participated in BRFSS in 2002. These data can be used to track state progress towards the national health objectives for 2010 for responsible sexual behavior. The 2002 BRFSS data represent the first time state data on contraceptive use in all 50 states will be presented and examined by selected sociodemographic characteristics. The 2002 BRFSS also, for the first time, provided an opportunity to examine state-level contraceptive use patterns among men.
RESULTS: Variation across states and territories was observed for the majority of contraceptive methods among the different demographics analyzed and among men and women. The percentage of men and women at risk for pregnancy who said they or their partner was using birth control was high overall and ranged from 67% (Guam) to 88% (Idaho). Oral contraceptives (i.e., the pill), vasectomy, tubal ligation, and condoms were the methods most frequently reported by both male and female respondents who said they or their partner was using birth control. Among female respondents using birth control, the pill was the most common method reported. Among men, vasectomy was the most commonly reported method. The prevalence of use for the four most commonly reported methods (pills, vasectomy, tubal ligation, condoms) varied as much as six-fold among states for vasectomy and three- to four-fold for condoms, pills, and tubal ligation.
INTERPRETATION: The findings in this report document substantial differences among states and sociodemographic groups within states in contraceptive method use. PUBLIC HEALTH ACTION: These data can help states identify populations with an unmet need for birth control, barriers to birth control use, and gaps in the range of birth control methods offered by health-care providers. An analysis of the prevalence of birth control use by state and selected population characteristics can help states target contraceptive programs to best meet the needs of their population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292246

Source DB:  PubMed          Journal:  MMWR Surveill Summ        ISSN: 1545-8636


  17 in total

1.  Racial and ethnic disparities in lifetime risk of corpus uterine cancer: a comparative study of Puerto Rico and the United States SEER population.

Authors:  Ana Patricia Ortiz; Yomayra Otero; Katherine Svensson; Omar García-Rodríguez; Sheyla Garced; Elvis Santiago; Sharee Umpierre; Nayda Figueroa; Karen J Ortiz-Ortiz
Journal:  Ethn Dis       Date:  2012       Impact factor: 1.847

2.  Geographic variations in female breast cancer incidence in relation to ambient air emissions of polycyclic aromatic hydrocarbons.

Authors:  Courtney Large; Yudan Wei
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-14       Impact factor: 4.223

3.  Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor.

Authors:  Tracy N Hadnott; Shaylyn S Stark; Alexa Medica; Andrew C Dietz; Maria Elena Martinez; Brian W Whitcomb; H Irene Su
Journal:  Fertil Steril       Date:  2019-04       Impact factor: 7.329

4.  Hormonal Contraception Use is Common Among Patients with Inflammatory Bowel Diseases and an Elevated Risk of Deep Vein Thrombosis.

Authors:  Cary C Cotton; Donna Baird; Robert S Sandler; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

5.  Patterns of postpartum depot medroxyprogesterone administration among low-income mothers.

Authors:  Ann M Dozier; Alice Nelson; Elizabeth A Brownell; Cynthia R Howard; Ruth A Lawrence
Journal:  J Womens Health (Larchmt)       Date:  2014-01-20       Impact factor: 2.681

Review 6.  Environmental and Genetic Risk Factors Associated with Venous Thromboembolism.

Authors:  Marta Crous-Bou; Laura B Harrington; Christopher Kabrhel
Journal:  Semin Thromb Hemost       Date:  2016-10-20       Impact factor: 4.180

7.  Comparability of contraceptive prevalence etimates for women from the 2002 Behavioral Risk Factor Surveillance System.

Authors:  John Santelli; Laura Duberstein Lindberg; Lawrence B Finer; Vaughn I Rickert; Diana Bensyl; Sam Posner; Shelly Makleff; Kathryn Kost; Susheela Singh
Journal:  Public Health Rep       Date:  2008 Mar-Apr       Impact factor: 2.792

Review 8.  Contraception for cancer survivors.

Authors:  Eleanor Bimla Schwarz; Rachel Hess; James Trussell
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

9.  Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.

Authors:  Ashley D Staton; Allison W Kurian; Kristin Cobb; Meredith A Mills; James M Ford
Journal:  Fam Cancer       Date:  2007-11-17       Impact factor: 2.375

10.  Reproductive health of the rapidly growing Hispanic population: data from the Pregnancy Risk Assessment Monitoring System, 2002.

Authors:  Jill A McDonald; Katherine Suellentrop; Leonard J Paulozzi; Brian Morrow
Journal:  Matern Child Health J       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.